2020, Volume 6, Issue 10
Engineering >> 2020, Volume 6, Issue 10 doi: 10.1016/j.eng.2020.02.006
Clinical Study of Mesenchymal Stem Cell Treatment for Acute Respiratory Distress Syndrome Induced by Epidemic Influenza A (H7N9) Infection: A Hint for COVID-19 Treatment
a State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, National Clinical Research Center for Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China
b Shulan （Hangzhou）Hospital Affiliated to Zhejiang Shuren University Shulan International Medical College, Hangzhou 310022, China
c Innovative Precision Medicine (IPM) Group, Hangzhou 311215, China
# These authors contributed equally to this work.
Next Previous
Abstract
H7N9 viruses quickly spread between mammalian hosts and carry the risk of human-to-human transmission, as shown by the 2013 outbreak. Acute respiratory distress syndrome (ARDS), lung failure, and acute pneumonia are major lung diseases in H7N9 patients. Transplantation of mesenchymal stem cells (MSCs) is a promising choice for treating virus-induced pneumonia, and was used to treat H7N9-induced ARDS in 2013. The transplant of MSCs into patients with H7N9-induced ARDS was conducted at a single center through an open-label clinical trial. Based on the principles of voluntariness and informed consent, 44 patients with H7N9-induced ARDS were included as a control group, while 17 patients with H7N9-induced ARDS acted as an experimental group with allogeneic menstrual-blood-derived MSCs. It was notable that MSC transplantation significantly lowered the mortality of the experimental group, compared with the control group (17.6% died in the experimental group while 54.5% died in the control group). Furthermore, MSC transplantation did not result in harmful effects in the bodies of four of the patients who were part of the five-year follow-up period. Collectively, these results suggest that MSCs significantly improve the survival rate of H7N9-induced ARDS and provide a theoretical basis for the treatment of H7N9-induced ARDS in both preclinical research and clinical studies. Because H7N9 and the coronavirus disease 2019 (COVID-19) share similar complications (e.g., ARDS and lung failure) and corresponding multi-organ dysfunction, MSC-based therapy could be a possible alternative for treating COVID-19.
Keywords
H7N9 ; Mesenchymal stem cell ; Epidemic Influenza A ; Acute respiratory distress syndrome ; COVID-19 ; Stem cell therapeutics
SupplementaryMaterials
Figures
Fig. 1
Fig. 2
References
[ 1 ] Rambaut A, Pybus OG, Nelson MI, Viboud C, Taubenberger JK, Holmes EC. The genomic and epidemiological dynamics of human influenza A virus. Nature 2008;453:615–9. link1
[ 2 ] Uyeki TM, Katz JM, Jernigan DB. Novel influenza A viruses and pandemic threats. Lancet 2017;389(10085):2172–4. link1
[ 3 ] Swayne DE, Suarez DL. Highly pathogenic avian influenza. Rev Sci Technol 2000;19:463–82. link1
[ 4 ] Gao R, Cao B, Hu Y, Feng Z, Wang D, Hu W, et al. Human infection with a novel avian-origin influenza A (H7N9) virus. N Engl J Med 2013;368:1888–97. link1
[ 5 ] Liu D, Shi W, Shi Y, Wang D, Xiao H, Li W, et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 2013;381:1926–32. link1
[ 6 ] Chen Y, Liang W, Yang S, Wu N, Gao H, Sheng J, et al. Human infections with the emerging avian influenza A H7N9 virus from wet market poultry: clinical analysis and characterisation of viral genome. Lancet 2013;381 (9881):1916–25. link1
[ 7 ] Li YH, Hu CY, Wu NP, Yao HP, Li LJ. Molecular characteristics, functions, and related pathogenicity of MERS-CoV proteins. Engineering 2019;5:940–7. link1
[ 8 ] Pantin-Jackwood MJ, Miller PJ, Spackman E, Swayne DE, Susta L, Costa-Hurtado M, et al. Role of poultry in the spread of novel H7N9 influenza virus in China. J Virol 2014;88(10):5381–90. link1
[ 9 ] Lee SS, Wong NS, Leung CC. Exposure to avian influenza H7N9 in farms and wet markets. Lancet 2013;381(9980):1815. link1
[10] Xu L, Bao L, Deng W, Dong L, Zhu H, Chen T, et al. Novel avian-origin human influenza A (H7N9) can be transmitted between ferrets via respiratory droplets. J Infect Dis 2014;209(4):551–6. link1
[11] Jonges M, Welkers MR, Jeeninga RE, Meijer A, Schneeberger P, Fouchier RA, et al. Emergence of the virulence-associated PB2 E627K substitution in a fatal human case of highly pathogenic avian influenza virus A (H7N7) infection as determined by Illumina ultra-deep sequencing. J Virol 2014;88:1694–702. link1
[12] Yu L, Wang Z, Chen Y, Ding W, Jia H, Chan JFW, et al. Clinical, virological, and histopathological manifestations of fatal human infections by avian influenza A (H7N9) virus. Clin Infect Dis 2013;57(10):1449–57. link1
[13] Robertson ID. Disease control, prevention and on-farm biosecurity: the role of veterinary epidemiology. Engineering 2020;6(1):20–5. link1
[14] Li Q, Zhou L, Zhou M, Chen Z, Li F, Wu H, et al. Epidemiology of human infections with avian influenza A (H7N9) virus in China. N Engl J Med 2014;370:520–32. link1
[15] Wang C, Yu H, Horby PW, Cao B, Wu P, Yang S, et al. Comparison of patients hospitalized with influenza A subtypes H7N9, H5N1, and 2009 pandemic H1N1. Clin Infect Dis 2014;58:1095–103. link1
[16] Zhou L, Ren R, Yang L, Bao C, Wu J, Wang D, et al. Sudden increase in human infection with avian influenza A (H7N9) virus in China, September–December 2016. Western Pac Surveill Response J 2017;8:6–14. link1
[17] Wang X, Jiang H, Wu P, Uyeki TM, Feng L, Lai S, et al. Epidemiology of avian influenza A H7N9 virus in human beings across five epidemics in mainland China, 2013–17: an epidemiological study of laboratory-confirmed case series. Lancet Infect Dis 2017;17:822–32. link1
[18] Zhou J, Wang D, Gao R, Zhao B, Song J, Qi X, et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013;499(7459):500–3. link1
[19] Wang B, Yao M, Lv L, Ling Z, Li L. The human microbiota in health and disease. Engineering 2017;3(1):71–82. link1
[20] Sivanandy P, Foong ZX, Lee WK, Wei YT, Kuan HE, Lian CL. A review on current trends in the treatment of human infection with H7N9-avian influenza A. J Infect Public Health 2018;12(2):153–8. link1
[21] Hui DS, Lee N, Chan PK, Beigel JH. The role of adjuvant immunomodulatory agents for treatment of severe influenza. Antivir Res 2018;150:202–16. link1
[22] Yang M, Gao H, Chen J, Xu X, Tang L, Yang Y, et al. Bacterial coinfection is associated with severity of avian influenza A (H7N9), and procalcitonin is a useful marker for early diagnosis. Diagn Microbiol Infect Dis 2016;84:165–9. link1
[23] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33. link1
[24] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395 (10223):497–506. link1
[25] Sahin AR, Erdogan A, Agaoglu PM, Dineri Y, Cakirci AY, Senel ME. 2019 novel coronavirus (COVID-19) outbreak: a review of the current literature. EJMO 2020;4(1):1–7. link1
[26] Li T, Lu H, Zhang W. Clinical observation and management of COVID-19 patients. Emerg Microbes Infect 2020;9(1):687–90. link1
[27] Chan JFW, Yuan S, Kok KH, To KKW, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-toperson transmission: a study of a family cluster. Lancet 2020;395 (10223):514–23. link1
[28] Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet 2020;395 (10226):809–15. link1
[29] Xu X, Wu X, Jiang X, Xu K, Ying L, Ma C, et al. Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-CoV-2) outside of Wuhan, China: retrospective case series. BMJ 2020;368:m606. link1
[30] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 2020;8(4):420–2. link1
[31] Wilson JG, Liu KD, Zhuo H, Caballero L, McMillan M, Fang X, et al. Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial. Lancet Respir Med 2015;3:24–32. link1
[32] Khoury M, Alcayaga-Miranda F, Illanes SE, Figueroa FE. The promising potential of menstrual stem cells for antenatal diagnosis and cell therapy. Front Immunol 2014;5:205. link1
[33] Chen L, Qu J, Cheng T, Chen X, Xiang C. Menstrual blood-derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases. Stem Cell Res Ther 2019;10:406. link1
[34] Chen L, Qu J, Xiang C. The multi-functional roles of menstrual bloodderived stem cells in regenerative medicine. Stem Cell Res Ther 2019;10 (1):1–10. link1
[35] Wang Q, Zhang Z, Shi Y, Jiang Y. Emerging H7N9 influenza A (novel reassortant avian-origin) pneumonia: radiologic findings. Radiology 2013;268:882–9. link1
[36] Gao HN, Lu HZ, Cao B, Du B, Shang H, Gan JH, et al. Clinical findings in 111 cases of influenza A (H7N9) virus infection. N Engl J Med 2013;368 (24):2277–85. link1
[37] Wu X, Luo Y, Chen J, Pan R, Xiang B, Du X, et al. Transplantation of human menstrual blood progenitor cells improves hyperglycemia by promoting endogenous progenitor differentiation in type 1 diabetic mice. Stem Cells Dev 2014;23(11):1245–57. link1
[38] Chen L, Zhang C, Chen L, Wang X, Xiang B, Wu X, et al. Human menstrual blood-derived stem cells ameliorate liver fibrosis in mice by targeting hepatic stellate cells via paracrine mediators. Stem Cells Transl Med 2017;6:272–84. link1
[39] Zheng G, Huang L, Tong H, Shu Q, Hu Y, Ge M, et al. Treatment of acute respiratory distress syndrome with allogeneic adipose-derived mesenchymal stem cells: a randomized, placebo-controlled pilot study. Respir Res 2014;15:39. link1
[40] McHugh LG, Milberg JA, Whitcomb ME, Schoene RB, Maunder RJ, Hudson LD. Recovery of function in survivors of the acute respiratory distress syndrome. Am J Respir Crit Care 1994;150(1):90–4. link1
[41] Herridge MS, Cheung AM, Tansey CM, Matte-Martyn A, Diaz-Granados N, AlSaidi F, et al. One-year outcomes in survivors of the acute respiratory distress syndrome. N Engl J Med 2003;348(8):683–93. link1
[42] Luyt CE, Combes A, Becquemin MH, Beigelman-Aubry C, Hatem S, Brun AL, et al. Long-term outcomes of pandemic 2009 influenza A (H1N1)-associated severe ARDS. Chest 2012;142:583–92. link1
[43] Lu PX, Wang YX, Zhou BP, Ge Y, Zhu WK, Chen XC, et al. Radiological features of lung changes caused by avian influenza subtype A H5N1 virus: report of two severe adult cases with regular follow-up. CMJ 2010;123(1):100–4. link1
[44] Bai L, Gu L, Cao B, Zhai XL, Lu M, Lu Y, et al. Clinical features of pneumonia caused by 2009 influenza A (H1N1) virus in Beijing, China. Chest 2011;139 (5):1156–64. link1
[45] Dowdy DW, Eid MP, Dennison CR, Mendez-Tellez PA, Herridge MS, Guallar E, et al. Quality of life after acute respiratory distress syndrome: a meta-analysis. Intens Care Med 2006;32:1115–24. link1
[46] Cohen J, Normile D. New SARS-like virus in China triggers alarm. Science 2020;367(6475):234–5. link1
[47] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;359:565–74. link1
[48] Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med 2020;382:1199–207. link1
[49] Zhou M, Zhang X, Qu J. Coronavirus disease 2019 (COVID-19): a clinical update. Front Med 2020;14(2):126–35. link1
[50] Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, et al. Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan China. JAMA 2020;323(11):1092–3. link1
[51] Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, et al. Ethical and safety issues of stem cell-based therapy. Int JMed Sci 2018;15(1):36–45 link1
[52] Gao F, Chiu SM, Motan DA, Zhang Z, Chen L, Ji HL, et al. Mesenchymal stem cells and immunomodulation: current status and future prospects. Cell Death Dis 2016;7:e2062. link1
[53] Shi M, Liu Z, Wang Y, Xu R, Sun Y, Zhang M, et al. A pilot study of mesenchymal stem cell therapy for acute liver allograft rejection. Stem Cells Transl Med 2017;6(12):2053–61. link1
[54] Xiang B, Chen L, Wang X, Zhao Y, Wang Y, Xiang C. Transplantation of menstrual blood-derived mesenchymal stem cells promotes the repair of LPS-induced acute lung injury. Int J Mol Sci 2017;18(4): E689. link1
[55] Hu C, Li L. Preconditioning influences mesenchymal stem cell properties in vitro and in vivo. J Cell Mol Med 2018;22(3):1428–42. link1
京公网安备 11010502051620号
